These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6349037)

  • 1. The influence of an angiotensin II antagonist, saralasin, given before donor nephrectomy, on kidney function after transplantation. A controlled prospective study.
    Huland H; Bause HW; Clausen C; Doehn N
    Transplantation; 1983 Aug; 36(2):139-42. PubMed ID: 6349037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and tubuloglomerular feedback effects of [Sar1,Ala8]angiotensin II in the rat.
    Ploth DW; Roy RN
    Am J Physiol; 1982 Feb; 242(2):F149-57. PubMed ID: 7039342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of angiotensin II inhibition on acute renal failure after intravascular coagulation in the rat.
    Ståhl E; Gerdin B; Rammer L
    Nephron; 1981; 29(5-6):250-7. PubMed ID: 7033809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of saralasin on renal function of the rat.
    Hofbauer KG; Bauereiss K; Zschiedrich H; Gross F
    Prog Biochem Pharmacol; 1976; 12():63-83. PubMed ID: 1019171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of the angiotensin II analog saralasin before donor nephrectomy on primary transplant function].
    Keller H; Kirste G; Wilms H; Knauf H
    Urologe A; 1986 Mar; 25(2):113-5. PubMed ID: 3521046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of administration of Sar1-Ala8-angiotensin II during the development and maintenance of renal hypertension in the rat.
    Fernandes M; Fiorentini R; Onesti G; Bellini G; Gould AB; Hessan H; Kim KE; Swartz C
    Clin Sci Mol Med; 1978 Jun; 54(6):633-7. PubMed ID: 657733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of the competitive angiotensin II antagonist saralasin during the initial phase of glycerol-induced acute renal failure of the rat.
    Greven J; Klein H
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Dec; 301(2):139-43. PubMed ID: 600326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of saralasin in preventing renal failure in ischemic transplanted kidneys.
    Munda R; Alexander JW
    Am Surg; 1980 Nov; 46(11):637-9. PubMed ID: 7001966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist and antagonist effects of Sar1-ala8--angiotensin II in salt-loaded and salt-depleted normal man.
    MacGregor GA; Dawes PM
    Br J Clin Pharmacol; 1976 Jun; 3(3):483-7. PubMed ID: 973974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic studies of infusions with [Sar 1, Val5, Ala8] angiotensin II (saralasin).
    Gless KH; Bönner G; Gram N; Mann JF; Helber A; Ganten D
    Klin Wochenschr; 1978; 56 Suppl 1():97-105. PubMed ID: 732257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of angiotensin II antagonist postischemic acute renal failure.
    Huland H; Augustin HJ; Engels T
    Urol Int; 1981; 36(1):15-22. PubMed ID: 7020205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of an angiotensin II antagonist to influence isoprenaline-induced antidiuresis in rats.
    Greven J; Pantel J
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):271-5. PubMed ID: 3713872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative studies of the humoral and arterial pressure responses to Sar1-Ala8-, Sar1-Ile8 and Sar1-Thr8-angiotensin II in the trained unanaesthetized dog.
    Bravo EL; Khosla MC; Bumpus FM
    Prog Biochem Pharmacol; 1976; 12():33-40. PubMed ID: 1019168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemodynamic effects of sar1-ala8-angiotensin in patients with renovascular hypertension (author's transl)].
    Philipp T; Zschierdrich H; Distler A
    Klin Wochenschr; 1977 Sep; 55(18):917-9. PubMed ID: 916618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [SAR1, ALA8]-Angiotensin II (saralasin): a symposium. Introduction.
    Vaughan ED; Peach MJ
    Kidney Int Suppl; 1979 Mar; (9):S1-2. PubMed ID: 289858
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo effects of angiotensin antagonists on plasma aldosterone in the dog.
    Beckerhoff R; Uhlschmid G; Furrer J; Nussberger J; Schmied UR; Vetter WJ; Siegenthaler W
    Eur J Pharmacol; 1975 Dec; 34(2):363-7. PubMed ID: 1234555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High renin activity accompanying angiotensin II inhibition in rats with ischemic renal failure.
    Shapira J; Iaina A; Eliahou HE; Solomon S
    Isr J Med Sci; 1976 Feb; 12(2):124-8. PubMed ID: 1262200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of saralasin in hypertensive patients on chronic hemodialysis.
    Lifschitz MD; Kirschenbaum MA; Rosenblatt SG; Gibney R
    Ann Intern Med; 1978 Jan; 88(1):23-7. PubMed ID: 619754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Historical development of saralasin.
    Pals DT; Denning GS; Keenan RE
    Kidney Int Suppl; 1979 Mar; (9):S7-10. PubMed ID: 384071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the renin-angiotensin system in post-transplantation hypertension in patients with multiple kidneys.
    Linas SL; Miller PD; McDonald KM; Stables DP; Katz F; Weil R; Schrier RW
    N Engl J Med; 1978 Jun; 298(26):1440-4. PubMed ID: 349389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.